Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3720 - Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) - Interim results of the non-interventional SCOPE study.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Prostate Cancer

Presenters

Juergen Gschwend

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

J. Gschwend1, C. Lange2, C. Bokemeyer3

Author affiliations

  • 1 Department Of Urology, Klinikum rechts der Isar, Technical University of Munich, Germany, 81675 - Munich/DE
  • 2 Urology, Medical Office Bernburg, 06406 - Bernburg/DE
  • 3 Department Of Oncology, Hematology And Bone Marrow Transplant, Hematology and Bone Marrow Transplant, University Medical Center Hamburg-Eppendorf, Germany, 20246 - Hamburg/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Abstract 3720

Background

Several treatment options are currently available for patients with mCRPC who were treated with a docetaxel-containing regimen. As one therapeutic option, cabazitaxel (CABA) in combination with prednis(ol)one can be administered. SCOPE is the first multinational, non-interventional study to address this question prospectively.

Methods

Within the ongoing SCOPE study, data on medical history, therapeutic management and outcome of mCRPC patients starting treatment with CABA under routine conditions are assessed with a target recruitment of 900 patients. For the current interim analysis (cut-off: MAR 16, 2018) descriptive statistics were used to analyze preliminary data on treatment outcomes.

Results

Of 551 enrolled patients, 137 patients (median age: 73 (47 to 88) years, ECOG of ≤ 1: 81.8%, median duration of CRPC at study inclusion: 20.4 (0.8 to 109.1) months) have completed CABA therapy. For 27 patients, first line therapy with an androgen-receptor targeted agent (ARTA) was documented (ARTA 1st line), of which 10 patients received an ARTA in 2nd line (ARTA post ARTA). None (0.0%) of the 10 ARTA post-ARTA patients had reductions in PSA levels ≥50% (PSA50 response) compared to baseline. Median progression-free survival (PFS) after the start of the respective therapy was longer for 1st line ARTA than for ARTA post-ARTA therapy (10.8 vs. 3.5 months, p = 0.0106). Fifty patients received docetaxel as 1st line therapy directly followed by CABA (CABA 2nd line) and for 24 patients ARTA therapy was documented after docetaxel and prior to CABA (CABA 3rd line). PSA50 response to CABA was 38.0% (CABA 2nd line) and 37.5% (CABA 3rd line), respectively. Median PFS after start of CABA therapy showed no significant differences between the CABA 2nd line and CABA 3rd line group (4.2 vs. 5.1 months, p = 0.5663).

Conclusions

The current results indicate that the outcome of ARTA post-ARTA is unfavourable compared to 1st line ARTA therapy and that CABA is effective in both ARTA and docetaxel refractory patients. However, interpretation of results is challenging due to the highly diverse treatment sequences administered in patients with mCRPC under routine conditions.

Clinical trial identification

BfArM data base No: 6658.

Legal entity responsible for the study

Sanofi Aventis Deutschland GmbH.

Funding

Sanofi Aventis Deutschand GmbH.

Editorial Acknowledgement

Disclosure

J. Gschwend: Lectures: Amgen, Astellas, Bayer, Janssen, MSD, Novartis, Roche, Sanofi; Advisor role: Bayer, BMS, Janssen, MSD, Novartis, Pfizer, Roche. C. Bokemeyer: Honoraria: Merck KGaA, Sanofi, Roche, Bayer, Brystol-Meyer Squibb, Servier/Pfizer, AstraZeneca; Consulting: Lilly/ImClone, Merck Serono, Sanofi, Mundipharma, Bayer Schering Pharma, Hexal. All other authors have declared no conflicts of interest.

Resources from the same session

4697 - Genetic signatures always suggest undertreatment? Experience with PAM51

Presenter: Carolina Sales

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.